Why combine three peptides in one blend?

Researchers combine a GHRH analog (CJC-1295) and a ghrelin agonist (Ipamorelin) because they act on separate receptors and synergistically amplify GH pulses, while Fragment 176-191 adds a direct lipolytic effect independent of the GH axis.

Does this blend require refrigeration?

Lyophilized peptide blends are typically stored frozen or refrigerated and kept refrigerated once reconstituted, protected from light, per standard peptide handling protocols.

← All peptides

Growth Hormone Secretagogues

Weight & Metabolic

Research Chemical

Fragment 176-191 / CJC-1295 / Ipamorelin Blend

Also known as: Fragment 176-191 & CJC-1295 & Ipamorelin, Fragment, CJC-1295, Ipamorelin, Fragment, Modified GRF, Ipamorelin

A three-part research blend combining the lipolytic HGH Fragment 176-191 with the GHRH analog CJC-1295 (No DAC) and the selective ghrelin-receptor agonist Ipamorelin. It is studied for its combined effect on endogenous growth hormone release and fat metabolism.

Mechanism of Action

CJC-1295 (No DAC), a modified GRF 1-29 analog, binds the pituitary GHRH receptor to amplify the amplitude of growth hormone pulses, while Ipamorelin selectively activates the GHS-R1a (ghrelin) receptor to trigger a discrete GH pulse without significantly raising cortisol or prolactin. The two secretagogues act through complementary, synergistic pathways to increase pulsatile GH and downstream IGF-1. HGH Fragment 176-191 is the C-terminal lipolytic domain of growth hormone and is thought to stimulate beta-3 adrenergic lipolysis and inhibit lipogenesis without the glucose-altering or IGF-1-mediated effects of full-length GH.

Half-life: Mixed: Ipamorelin ~2 hours, CJC-1295 (No DAC) ~30 minutes, HGH Fragment 176-191 ~20-30 minutes
Administration Routes: subcutaneous
Research Status: Research Chemical